ANEW Medical (WENA) said Thursday it has partnered with researchers at Japan's Okinawa Research Center for Longevity Science for the development of its Klotho gene therapy in reducing age-related diseases.
Okinawa is among a set of global "Blue Zones" with high numbers of people who live to high ages and remain in good health.
ANEW said preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform may contribute to long lifespans and protection against diseases such as Alzheimer's Disease. The company is developing a portfolio of therapies targeting the gene.
Price: 3.4200, Change: -0.20, Percent Change: -5.52
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。